Pricing Log in Create free account
Friday 6 November 2026 Export NBIX’s income statement to Excel — free account

Neurocrine Biosciences, Inc.

NBIX Healthcare Drug Manufacturers Specialty & Generic

Neurocrine Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 21.4% from fiscal 2024.

Revenue
+41.2%
EPS
−3.67%
Free cash flow
+79.0%

Quarter to September 2026, against a year earlier

164.75 4.99 +3.12%
Market cap
$16.2B
P/E
23.0×
Fwd P/E
20.6×
Dividend yield
—
F-score
7/9
Altman Z
7.80
Beneish M
−2.64
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Neurocrine Biosciences, Inc. 10-Q filed Nov 2, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed · accepted 4:14 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Jul 31, 2026: 8 added · 1 removed · 13 modified; 10 with only figures updated

  1. Modified · 2026 Business Highlights

    •In May 2026, we entered into a $1.0 billion senior secured revolving credit facility (the 2026 Credit Facility). In June 2026, we repaid $600.0 million of principal that was borrowed under the 2026 Credit Facility in May 2026. As of JuneSeptember 30, 2026, we had $1.0 billion of available borrowing capacity under the 2026 Credit Facility. We may use borrowings under the 2026 Credit Facility for general corporate purposes and other purposes permitted by the credit agreement. Our ability to borrow under the 2026 Credit Facility is subject to the satisfaction of customary conditions, including compliance with the covenants contained in the credit agreement.

21 more changes in this Item, word by word, in Powerpack.